64 results about "Lisinopril" patented technology

A stable pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutical acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. % of hydroxypropyl cellulose, wherein the ACE inhibitor is selected from the group consisting of quinapril, enalapril, spirapril, ramipril, perindopril, indolapril, lisinopril, alacepril, trandolapril, benazapril, libenzapril, delapril, cilazapril and combinations thereof; wherein the formation of an internal cyclization product, and / or ester hydrolysis product, and / or oxidation product, has been reduced or eliminated, and the weight percents are based on the total weight of the pharmaceutical composition. The stabilized pharmaceutical compositions of the invention exhibit a number of advantages as follows: (i) the ACE inhibitor or a pharmaceutical acceptable salt thereof present in the compositions is preserved from degradation; (ii) the compositions exhibit extended shelf-life under normal storage conditions; (iii) the effect of moisture on the compositions is minimized; (iv) the compositions exhibit minimal, if any, discoloration over a significant period of time; and (v) the compositions exhibit minimal, if any, instability when employed in the presence of colorants.

Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

The invention relates to a lisinopril-containing compound preparation for treating hypertension, which comprises the main components of L-amlodipine or pharmaceutically acceptable salt thereof, hydrochlorothiazide and lisinopril or pharmaceutically acceptable salt thereof, and the auxiliary component of a pharmaceutically acceptable carrier, wherein the content of the L-amlodipine or the pharmaceutically acceptable salt thereof in unit preparation is 2.5-10.0mg. The invention has the advantages of fully exerting medicine compensation action mechanism through medicine combination therapy, increasing curative effect, quickly reaching the standards, making the compliance rate of blood pressure reach 82%, reducing adverse effect associated with the dose increase of certain medicine and keeping longer action time. The compound preparation has the characteristics of quick effect taking, high compliance rate of blood pressure, little side effect and low cost.

The invention relates to the technical fields of sustained release tablets and preparation thereof and particularly relates to a lisinopril sustained release tablet and a preparation method thereof. The lisinopril sustained release tablet is formed by a tablet core containing lisinopril and a coating layer packaging the tablet core, wherein the coating layer is prepared from non-water-soluble coating materials. The lisinopril sustained release tablet is characterized in that the tablet core contains the following substances in parts by weight: 5.0%-10 parts of lisinopril and 40-70 parts of a porous carbon material. The lisinopril sustained release tablet has a release delaying effect and a sustained release effect; and the preparation method is simple in process, wide in raw material source and beneficial to industrial production.

A precursor of lisinopril is prepared from activated alpha bromoacid and proline or its derivative through condensation to generate bipeptide, closing cycle in molecular under the action of strong alkali, opening lactone cycle by alkali in solvent to obtain the compound containing free hydroxy and carboxy, protecting or activating said two radicals, and condensating with high-benzene ethyl lactamate. Its advantages are high output rate and no pollution.

A method for preparing a lisinopril intermediate is provided. The method includes: treating (R)-hydroxy-4-phenylbutyrate with sulfonyl chloride in an organic solvent in the presence of a base to obtain a solution of sulfonate; reacting the obtained solution with a salt of trifluoroacetyl lysine; and obtaining a N2-[1-(S)-alkoxycarbonyl-3-phenylpropyl]-N6-trifluoroacetyl-L-lysine by separating after the reaction is completed. The method provided has a shorter synthesis route, is easy to operate, has a low cost, and is suitable for industrial production.

The invention belongs to the technical field of medicines, and in particular to a stable lisinopril tablet and a preparation method thereof. The stable lisinopril tablet is prepared by dry granulation, and is coated, so that a series of adverse consequences resulting from moisture absorption of the tablet can be avoided, and the product quality is more stable.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition containing lisinopril and amlodipine besylate and a preparation method of the pharmaceutical composition. The pharmaceutical composition comprises the following components in parts by weight: 10 parts of lisinopril, 5 parts of amlodipine besylate (based on the weight of amlodipine), 100-200 parts of microcrystalline cellulose, 6-10 parts of sodium carboxymethyl starch, 1-3 parts of fumed silica and 2-4 parts of magnesium stearate. The pharmaceutical composition is prepared by using a dry granulating tableting process. The pharmaceutical composition has reasonable formula and good stability. The preparation method is simple in process and high in production efficiency; the preparation process of the pharmaceutical composition does not cause the increase of impurity content; the content uniformity of the prepared pharmaceutical composition is good.

Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.

The invention provides a method for preparing a lisinopril intermediate. The lisinopril intermediate is (R)-2-hydroxyl-4-phenylbutyrate. The method has the advantages that the lisinopril intermediate is made of inexpensive and easily available raw materials which are benzaldehyde and pyruvic acid, four-step efficient reaction including condensation, biological enzyme catalytic asymmetric reduction, double-bond hydrogenation and esterification is carried out on the benzaldehyde and the pyruvic acid, and accordingly an optically pure target product (R)-HPBE [(R)-2-hydroxyl-4-phenylbutyrate] can be ultimately obtained at the overall yield of 83%.